The CHK2 kinase is recurrently mutated and functionally impaired in the germline of pediatric cancer patients

Int J Cancer. 2023 Apr 1;152(7):1388-1398. doi: 10.1002/ijc.34390. Epub 2022 Dec 27.

Abstract

Predisposing CHEK2 germline variants are associated with various adult-type malignancies, whereas their impact on cancer susceptibility in childhood cancer is unclear. To understand the frequency of germline variants in the CHEK2 gene and their impact on pediatric malignancies, we used whole-exome sequencing to search for CHEK2 variants in the germlines of 418 children diagnosed with cancer in our clinics. Moreover, we performed functional analysis of the pathogenic CHEK2 variants to analyze the effect of the alterations on CHK2 protein function. We detected a CHEK2 germline variant in 32/418 (7.7%) pediatric cancer patients and 46.8% of them had leukemia. Functional analysis of the pathogenic variants revealed that 5 pathogenic variants impaired CHK2 protein function. 6/32 patients carried one of these clearly damaging CHEK2 variants and two of them harbored a matching family history of cancer. In conclusion, we detected germline CHEK2 variants in 7.7% of all pediatric cancer patients, of which a minority but still relevant fraction of approximately 20% had a profound impact on protein expression or its phosphorylation after irradiation-induced DNA damage. Accordingly, we conclude that CHEK2 variants increase the risk for not only adult-onset but also pediatric cancer.

Keywords: CHEK2; cancer predisposition; leukemia; pediatric cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Breast Neoplasms*
  • Checkpoint Kinase 2 / genetics
  • Child
  • DNA Damage / genetics
  • Female
  • Genetic Predisposition to Disease
  • Germ Cells
  • Germ-Line Mutation
  • Humans
  • Neoplasms* / genetics

Substances

  • Checkpoint Kinase 2
  • CHEK2 protein, human